Attached files
file | filename |
---|---|
EX-99.2 - EXHIBIT 99.2 - Lexaria Bioscience Corp. | exhibit99-2.htm |
8-K - FORM 8-K - Lexaria Bioscience Corp. | form8k.htm |
Exhibit 99.1
Lexaria Featured on Television
Kelowna, BC / May 18, 2017 / Lexaria Bioscience Corp. (OTCQB:LXRP) (CSE:LXX) (the Company or Lexaria) is one of five companies featured on a special BTV episode exploring burgeoning cannabis enterprises.
Lexarias patented technology is showcased amongst leading Canadian cannabis companies and will be aired on the following schedule:
CANADA:
BNN and Bell Express Vu
Saturday
May 20 @ 5:00pm PST
Sunday May 21 @ 6:30pm PST
Air Canada: TV seatback Business Channel
U.S.:
Biz Television Network
Sunday May 28
@ 10:00pm & 4:30pm PST,
Saturday June 3 @ 9:00pm PST
The half-hour program is also available online at BTV. You can click to watch the Full Episode.
Lexaria has 18 patents pending and patent applications filed in more than 40 countries worldwide.
About Lexaria
Lexaria Bioscience Corp. is a food biosciences company with a
proprietary technology for improved delivery of bioactive compounds. The
Companys lipophilic enhancement technology has been shown to enhance the
bioavailability of orally ingested cannabinoids, while also improving taste.
This technology promotes healthy ingestion methods, lower overall dosing and
higher effectiveness in active molecule delivery. The Companys technology is
patent-protected for cannabidiol (CBD) and all other non-psychoactive
cannabinoids, and patent-pending for Tetrahydrocannabinol (THC), other
psychoactive cannabinoids, non-steroidal anti-inflammatory drugs (NSAIDs),
nicotine and other molecules.
www.lexariabioscience.com
FOR FURTHER INFORMATION PLEASE CONTACT:
Lexaria Bioscience
Corp.
Chris Bunka
Chairman & CEO
(250) 765-6424
FORWARD-LOOKING STATEMENTS
This release includes
forward-looking statements. Statements which are not historical facts are
forward-looking statements. The Company makes forward-looking public statements
concerning its expected future financial position, results of operations, cash
flows, financing plans, business strategy, products and services, competitive
positions, growth opportunities, plans and objectives of management for future
operations, including statements that include words such as "anticipate," "if,"
"believe," "plan," "estimate," "expect," "intend," "may," "could," "should,"
"will," and other similar expressions are forward-looking statements, including
but not limited to: that any additional stock warrants or stock options will be
exercised. Such forward-looking statements are estimates reflecting the
Company's best judgment based upon current information and involve a number of
risks and uncertainties, and there can be no assurance that other factors will
not affect the accuracy of such forward-looking statements. There is no
assurance that the Company will be able to raise required working capital.
Factors which could cause actual results to differ materially from those
estimated by the Company include, but are not limited to, government regulation,
managing and maintaining growth, the effect of adverse publicity, litigation,
competition, the patent application and approval process and other factors which
may be identified from time to time in the Company's public announcements and
filings. There is no assurance that existing capital is sufficient for the
Company's needs or that it will be able to raise additional capital. There is no
assurance that Lexaria will successfully complete any other contemplated or
existing technology license agreements; that the expected studies will be
carried out with NRC as expected; or that results from any studies will be
favorable or in any way support future business activities of any kind. There is
no assurance that any planned corporate activity, business venture, or
initiative will be pursued, or if pursued, will be successful. There is no
assurance that any of Lexarias postulated uses, benefits, or advantages for the
patented and patent-pending technology will in fact be realized in any manner or
in any part. No statement herein has been evaluated by the Food and Drug
Administration (FDA). Lexaria Energy Foods and ViPovaTM products are
not intended to diagnose, treat, cure or prevent any disease.
The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.